EIKN Company Profile and Key Details

Eikon Therapeutics, Inc. Common Stock has 54.17 million shares outstanding. The public float is 29.87 million shares, elevated short interest at 11.97% of float. This equals 4.88 million shares. The short ratio is 15.05 days. Institutional investors hold 80.79% of the float. Insiders own 17.39%.

Analyst sentiment is bearish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $34.00 to $5.00. The high target offers 318.2% upside. The low target suggests -38.5% downside. The mean target is $20.00. This offers 146.0% upside. Eikon Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 3.16%. The prior quarter beat by 29.49%. Over the last six quarters, Apple has recorded several small beats. These include 658.43% in March 30, 2026.

Eikon Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.82. This means the shares are trading below this model’s fair value.

Short-term trend indicators are mixed aligned (SMA20 -7.95%, SMA50 -7.95%, SMA200 -7.95%). The stock’s 14-day RSI is 41.12 (neutral), while the ATR of 1.61 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -21.61% below its high and over 2.67% above its low. Average 10-day trading volume of 945.68 thousand shares is significantly above the 3-month average of 513.70 thousand, indicating heightened recent market interest.

Eikon Therapeutics, Inc. Common Stock (NASDAQ:EIKN) closed at $8.13 USD, losing -$0.85 (-9.47%) from the previous close of $8.98. The stock is currently within 5% of its 52-week low $7.90 and $17.40. With a market capitalization of about $440.15 million, Eikon Therapeutics, Inc. Common Stock is classified as a small-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 516.32 thousand shares, in line with its 52-week average. Headquartered in Millbrae, CA, Eikon Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Roger Perlmutter, the company employs approximately 384 people and listed since February 05, 2026. Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States.

Eikon Therapeutics, Inc. Common Stock trades at a P/E ratio of -1.76, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.94 suggesting the stock is closer to book value. The P/FCF stands at -1.7, also below market averages.

currently trading near 52-week highs band. Valuation shows Eikon Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -1.76. Analyst sentiment is cautious, with the majority of ratings in Underperform territory and a mean price target of $20.00, suggesting 146.0% upside. Our AI forecast model points to short-term weakness (-15.5% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-80.81% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Eikon Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.5%, with price expected at $6.87 by October 05, 2026, within a range of $6.28 to $7.46 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 18, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected loss of -80.81%, with price at $1.56 by September 21, 2027, within a range of $1.38 to $1.74.